*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Everest Medicines Limited**
**雲頂新耀有限公司**
*(incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1952)**

# VOLUNTARY ANNOUNCEMENT
# INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that on 31 December 2025, Mr. Yifang Wu ("**Mr. Wu**"), an executive Director and the chairman of the Board, purchased 30,000 ordinary shares of the Company (the "**Share(s)**") on the market for a total consideration of approximately HK$1,139,000, representing an average price of approximately HK$37.98 per Share.

The Board believes that a voluntary share purchase through on-market acquisitions of Shares by Mr. Wu signifies strong confidence in the future prospects and long-term development of the Company.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
**Everest Medicines Limited**
**Yifang Wu**
*Chairman and Executive Director*

Hong Kong, 31 December 2025

*As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*